Cardiavent Inc.
3991 Ramsgate Ct.
Ann Arbor, MI 48013

Cardiavent Inc.  

The companies’ strength centers on our experience and high technology.
  • Cardiavent founded in 2009 to develop CARD-024 for renal and cardiovascular disease
  • CARD-024 discovered based on understanding of vitamin D metabolism
    • Chemical structure modifications to eliminate absorption from duodenal enterocytes, and decrease induction of intestinal calcium absorption.
    • Preclinical and Phase 1 studies demonstrate biologic activity without induction of hypercalcemia.
  • Potential best-in-class treatment for secondary hyperparathyroidism (> $700 million market in the US in 2012):
    • Addresses main toxicity issue with current therapies.
    • Rapid development pathway  to NDA approval.
    • Broad therapeutic index supports potential for superior efficacy in reaching target PTH levels and for less frequent safety monitoring.
  • Potential best-in-class treatment for TGF-beta induced fibrosis in Crohn's Disease.
    • Inhibits TGF-beta induced markers of intestinal fibrosis alpha-SMA and pFAK

Website Builder